U.K. watchdogs reject Vertex's CF med Orkambi, citing $147K annual cost

Vertex Pharmaceuticals ($VRTX) is facing a roadblock in the U.K. for its new, pricey cystic fibrosis treatment Orkambi. The country's National Institute for Health and Care Excellence (NICE) recommended against funding the drug, saying that it did not demonstrate enough benefits to patients to justify its high cost. Report

Suggested Articles

Moving into the Final Four of the #FierceMadness drug name tournament, contenders from both Big Pharma and smaller companies remain evenly in play.

Eli Lilly bought full-page ads in more than a dozen newspapers in the U.S. to let people with diabetes who use Lilly drugs to know help is available.

Only months after a game-changing new approval for Vascepa, Amarin has lost a key fight over its patents—and now it's scrambling to respond.